换一批程序性死亡受体1及其配体在胃癌免疫治疗中的研究进展
Progress of programmed death 1 and its ligand in treatment of gastric cancer
摘要程序性死亡受体1/程序性死亡受体1配体(PD-1/PD-L1)靶点阻断剂已被美国食品药品监督管理局(FDA)批准用于治疗黑色素瘤、非小细胞肺癌、肾癌等实体肿瘤,随后对胃肠道实体肿瘤治疗也开展了初步研究,并取得了一定疗效,显示了较好的应用前景,但同时也发现一些局限性.文章对免疫治疗在胃癌治疗中的研究进展进行综述.
更多相关知识
abstractsImmunotherapy targeted on programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) has been approved by US Food and Drug Administration (FDA) for the treatment of solid tumors such as melanoma, non-small cell lung cancer and renal cell carcinoma. Preliminary study on the gastrointestinal solid tumor has been carried out, which has shown favorable efficacies and promising application prospect. However, some disadvantages have appeared. This article reviews the progress of immunotherapy for gastric adenocarcinoma.
More相关知识
关键词
胃肿瘤免疫疗法程序性死亡受体1程序性死亡受体1配体Stomach neoplasmsImmunotherapyProgrammed death 1Programmed death 1 ligand
栏目名称
DOI
10.3760/cma.j.issn.1006-9801.2018.01.016
发布时间
2018-02-05（万方平台首次上网日期，不代表论文的发表时间）
基金项目
山西省科技攻关计划（(20150313007-7)）
Shanxi Science and Technology Research Program （(20150313007-7)）
- 浏览320
- 被引8
- 下载400
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
